RxDoctor Payments Data

Ludy Shih, MD

Neurology · Boston, MANPI 1720068661

Payments from drug & device makers

$6,677in general payments, 2019–2025

Across 23 payments — averaging $290.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$3K
  • MDD US Operations, LLC$2K
  • Biogen$750
  • Bayer$298
  • Medtronic$170
  • Takeda Pharmaceuticals U.S.A., Inc.$105
  • plus $159 from 4 others
$18,500in research payments, 2019–2025

Across 18 payments — averaging $1027.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$19K

What the payments were for

  • Consulting fees$5,94589%
  • Travel & lodging$671%
  • Food & beverage$66310%
  • Education$20%

General payments by program year

19
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,677 in reported general payments places this provider in the 65th percentile of 761 neurology providers in Massachusetts.

See all neurology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$49,418
Medicare patients
186
Services billed
561

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine13$122,196
RytaryCarbidopa/Levodopa12$30,420
Carbidopa-LevodopaCarbidopa/Levodopa249$9,134
Carbidopa-Levodopa ErCarbidopa/Levodopa73$4,771
Rasagiline Mesylate18$4,555
Entacapone24$3,646
AmantadineAmantadine Hcl53$1,896
Primidone104$1,724
Ropinirole ErRopinirole Hcl14$1,458
Propranolol Hcl38$1,168
Propranolol Hcl ErPropranolol Hcl21$923
Trospium Chloride11$758
Gabapentin34$565
Donepezil Hcl34$497
Pramipexole DihydrochloridePramipexole Di-Hcl14$391

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$41$122,19613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 761 neurology providers in Massachusetts.

Other neurology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →